ASTRIS: A multicenter, real world treatment study of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Cheema, P. K. [1 ]
Chen, Y-M. [2 ]
de Marinis, F. [3 ]
Freitas, H. C. [4 ]
Kim, S-W. [5 ]
Milner, A. [6 ]
Provencio, M. [7 ]
Rigas, J. [6 ]
Wu, Y-L. [8 ]
机构：
[1] Sunnybrook HSC, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[2] Natl Yang Ming Univ, Taipei, Taiwan
[3] Ist Europeo Milan, Div Thorac Oncol, Milan, Italy
[4] AC Camargo Canc Ctr, Sao Paulo, Brazil
[5] Asan Med Ctr, Seoul, South Korea
[6] AstraZeneca, Cambridge, England
[7] Hosp Clin Barcelona, Barcelona, Spain
[8] Guangdong Gen Hosp, Guangdon Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
141TiP
引用
收藏
页数：2
相关论文
共 50 条
  • [21] The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
    Gao, Xin
    Le, Xiuning
    Costa, Daniel B.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (04) : 383 - 390
  • [22] Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation
    Imamura, Fumio
    Kimura, Madoka
    Yano, Yukihiro
    Mori, Masahide
    Suzuki, Hidekazu
    Hirashima, Tomonori
    Ihara, Shouichi
    Komuta, Kiyoshi
    Shiroyama, Takayuki
    Nagatomo, Izumi
    Kumagai, Toru
    FUTURE ONCOLOGY, 2020, 16 (21) : 1537 - 1546
  • [23] Mixed Response of Non-Small Cell Lung Cancer Harboring the EGFR T790M Mutation to Osimertinib
    Shinno, Y.
    Goto, Y.
    Sato, J.
    Morita, R.
    Matsumoto, Y.
    Murakami, S.
    Kanda, S.
    Horinouchi, H.
    Fujiwara, Y.
    Yamamoto, N.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2145 - S2145
  • [24] An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer
    Wang, Jingyi
    Wu, Lin
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (06) : 647 - 652
  • [25] Sequential treatment of afatinib followed by osimertinib in T790M EGFR mutation positive non-small-cell lung cancer (NSCLC) pa tients: an observational study
    Hochmair, M.
    Morabito, A.
    Hao, D.
    Yang, C. -T.
    Soo, R. A.
    Gucalp, R.
    Halmos, B.
    Wang, L.
    Golembesky, A.
    Maerten, A.
    Cufer, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 75 - 75
  • [26] Osimertinib in previously EGFR-TKI treated non-small cell lung cancer (NSCLC) patients without T790M mutation: Real-world evidence.
    Luo, Yung-Hung
    Liu, Han
    Wampfler, Jason A.
    Tazelaar, Henry D.
    Li, Yalun
    Peikert, Tobias
    Liu, Dan
    Leventakos, Konstantinos
    Chen, Yuh-Min
    Yang, Yanan
    Chiou, Shih-Hwa
    Yang, Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
    Zheng, Qiufan
    Hong, Shaodong
    Huang, Yan
    Zhao, Hongyun
    Yang, Yunpeng
    Hou, Xue
    Zhao, Yuanyuan
    Ma, Yuxiang
    Zhou, Ting
    Zhang, Yaxiong
    Fang, Wenfeng
    Zhang, Li
    CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 9 (01):
  • [28] Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer
    Choo, Joan Rou-En
    Tan, Chee-Seng
    Soo, Ross A.
    TARGETED ONCOLOGY, 2018, 13 (02) : 141 - 156
  • [29] Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer
    Joan Rou-En Choo
    Chee-Seng Tan
    Ross A. Soo
    Targeted Oncology, 2018, 13 : 141 - 156
  • [30] Osimertinib as a Potential Targeted Therapy for Non-Small Cell Lung Carcinoma (NSCLC) Patients with EGFR Exon 20 T790M
    Zam, Nur Zam
    Iskandar, Harun
    Tabri, Nur Ahmad
    Santoso, Arif
    Lihawa, Nurjannah
    Putrawan, Harry Akza
    Sandra, Ferry
    INDONESIAN BIOMEDICAL JOURNAL, 2023, 15 (05): : 336 - 340
12345